Protheragen, a professional service provider specializing in advanced drug delivery system development, announced the launch of integrated solutions encompassing hydrogel drug delivery systems, microneedle development, and lyophilized flash release formulations. These offerings aim to provide diversified and customizable novel drug delivery system options to the global pharmaceutical and biomedical industries, targeting key challenges in traditional drug administration such as unstable efficacy, low bioavailability, frequent dosing, and limited targeting capabilities.
The hydrogel drug delivery system from Protheragen utilizes hydrogels' biocompatibility and three-dimensional cross-linked polymer network to encapsulate therapeutic substances including small molecules, proteins, peptides, and nucleic acids. The hydrogel platforms can be engineered to respond to stimuli such as pH, temperature, and enzymes, enabling targeted and sustained drug release at specific body sites to minimize off-target side effects and improve the therapeutic index. Protheragen develops multiple practical hydrogel formulations tailored to diverse administration routes, including injectable, implantable, ocular, transdermal, oral, and nanoparticle-combined hydrogels. Injectable hydrogels transition from liquid to solid gel under physiological conditions for long-term sustained release, while ocular hydrogels can be integrated into contact lenses for non-invasive eye medication delivery. The company also employs both physical and chemical crosslinking methods to regulate hydrogel degradation, swelling, and deformation, achieving precise control over drug release rates.
Protheragen's professional microneedle development services focus on transdermal drug delivery, a novel system using micron-sized needles to penetrate the skin's stratum corneum and deliver drugs directly to subcutaneous tissues. This technology bypasses gastrointestinal metabolism, enhancing drug bioavailability and enabling localized treatment to reduce systemic adverse reactions. Protheragen develops five mainstream microneedle types: coated, dissolving, hollow, hydrogel-forming, and solid microneedles, supporting delivery approaches such as "coat and poke" and "poke and release." From material selection and structural design to formulation optimization, preclinical evaluation, and production scale-up, the one-stop microneedle development workflow meets personalized demands of different drugs and treatment scenarios.
The lyophilized flash release formulation development service combines freeze-drying and flash-release technologies to optimize drug stability and release performance. Lyophilization converts liquid drugs into solid forms such as particles, films, and microspheres, extending shelf life and protecting active pharmaceutical ingredients from degradation. Equipped with controlled release technologies, these formulations realize rapid or timed drug release after administration, covering oral, injectable, and topical application scenarios. Protheragen optimizes the entire production process from initial demand consultation and formulation design to freeze-drying parameter adjustment and quality testing, ensuring each batch complies with strict regulatory standards and facilitating commercial production and market approval for clients.
Collectively, these drug delivery system solutions deliver comprehensive services for global pharmaceutical and biomedical clients. With flexible customization capabilities, Protheragen's services adapt to drugs of different properties and clinical needs, helping research institutions and pharmaceutical enterprises accelerate the research and transformation of new drugs.
